Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 2/20 | 0.44 |
| ▸ | TACR1 | P25103 | 1/20 | 0.35 |
| ▸ | TACR3 | P29371 | 1/20 | 0.35 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.34 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.34 |
| ▸ | MMP1 | P03956 | 1/20 | 0.31 |
| ▸ | MMP3 | P08254 | 1/20 | 0.31 |
| ▸ | MMP9 | P14780 | 1/20 | 0.31 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21536833 | 0.90 | GRIA1 (0.37) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL16589749 | 0.88 | GRIA1 (0.44) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL16589722 | 0.88 | GRIA1 (0.44) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL20623017 | 0.84 | GRIA1 (0.37) | GRIA1TACR1TACR3 | |
| SCHEMBL16589738 | 0.84 | GRIA1 (0.46) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL19756271 | 0.84 | GRIA1 (0.35) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL16589725 | 0.83 | GRIA1 (0.45) | GRIA1TACR1TACR3SIRT6SIRT1 | |
| SCHEMBL16589748 | 0.82 | CCKBR (0.45) | GRIA1SIRT6SIRT1 | |
| SCHEMBL19756273 | 0.82 | KDM4E (0.36) | GRIA1MMP1 | |
| SCHEMBL16589723 | 0.81 | GRIA1 (0.44) | GRIA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2023-01-31 | — | — | US | disclosed |
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-12-29 | — | — | US | disclosed |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2022-07-07 | — | — | US | disclosed |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-26 | — | — | US | disclosed |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-04-21 | — | — | US | disclosed |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2022-01-18 | — | — | US | disclosed |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-10-26 | — | — | US | disclosed |
| US-20210177942-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2021-06-17 | — | — | US | disclosed |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS AS (DK) | 2021-03-18 | — | — | US | disclosed |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-11-17 | — | — | US | disclosed |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2020-09-03 | — | — | US | disclosed |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-10-31 | — | — | US | disclosed |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-24 | — | — | US | disclosed |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-17 | — | — | US | disclosed |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2019-01-03 | — | — | US | disclosed |
| US-20170368189-A1 | CNP PRODRUGS | ASCENDIS PHARMA GROWTH DISORDERS A/S (DK) | 2017-12-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220409700-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH REDUCED SIDE-EFFECTS | CNP, NPR1, NTSR2 | GRIA1 639/4885TACR1 99/4885TACR3 151/4885 |
| US-11154593-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20190328840-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW INITIAL NPR-B ACTIVITY | NPR1, NPR3, CNP | GRIA1 723/4885TACR1 131/4885TACR3 81/4885 |
| US-20200276270-A1 | Combination Therapy with Controlled-Release CNP Agonists | CNP, NPR1, NGF | GRIA1 778/4885TACR1 137/4885TACR3 310/4885 |
| US-20190022237-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH INCREASED NEP STABILITY | CNP, NPR1, NPPA | GRIA1 1507/4885TACR1 109/4885TACR3 101/4885 |
| US-20190000926-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-20210077584-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20220211817-A1 | CONTROLLED-RELEASE CNP AGONISTS WITH LOW NPR-C BINDING | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-11311604-B2 | Controlled-release CNP agonists with low NPR-C binding | NPR1, NPR3, NPSR1 | GRIA1 567/4885TACR1 24/4885TACR3 53/4885 |
| US-11224661-B2 | Controlled-release CNP agonists with increased NEP stability | CNP, NPR1, NPPA | GRIA1 1507/4885TACR1 109/4885TACR3 101/4885 |
| US-20210177942-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20220118053-A1 | Dry Pharmaceutical Formulations of CNP Conjugates | CNP, PTMS, NPPA | GRIA1 2197/4885TACR1 164/4885TACR3 137/4885 |
| US-11564974-B2 | Combination therapy with controlled-release CNP agonists | CNP, NPR1, NGF | GRIA1 778/4885TACR1 137/4885TACR3 310/4885 |
| US-10835578-B2 | CNP prodrugs with large carrier moieties | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20190015481-A1 | CNP PRODRUGS WITH LARGE CARRIER MOIETIES | CNP, LNPEP, CSGALNACT1 | GRIA1 3132/4885TACR1 362/4885TACR3 1017/4885 |
| US-20170368189-A1 | CNP PRODRUGS | NPPA, NPR1, NPR3 | GRIA1 3408/4885TACR1 64/4885TACR3 166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.